Patents and access to essential medicines

Frontiers of Economics and Globalization

Volumn 2, Issue , 2008, Pages 423-464

  Croix, Sumner La ^a   Liu, Ming ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Buyouts; Patents; Pharmaceuticals; Price discrimination; RandD; TRIPS

Indexed keywords

EID: 84898953357     PISSN: 15748715     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1574-8715(07)00013-9     Document Type: Review

References (87)

1. Abbott, F.M. (2001), The TRIPS Agreement, Access to Medicines and theWTO Doha Ministerial Conference. Public Law and Legal Theory, Working Paper No. 7. Available at: http://papers.ssrn.com/abstract=285934. (Last accessed on December 4, 2006.)
2. Acemoglu, D., Linn, J. (2004), Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics 119 (3), 1149-1190.
3. Attaran, A., Gillespie-White, L. (2001), Do patents for anti-retroviral drugs constrain access to HIV/AIDS treatment in Africa? Journal of the American Medical Association 286 (15), 1886-1892.
4. Bale, H.E. (1998), The conflicts between parallel trade and product access and innovation: The case of pharmaceuticals. Journal of International Economic Law 1 (4), 637-653.
5. Barfield, C.E., Groombridge, M.A. (1998), The economic case for copyright owner control over parallel imports. Journal of World Intellectual Property 1 (6), 903-939.
6. Baumol, W.J., Bradford, D.F. (1970), Optimal departures from marginal cost pricing. American Economic Review 60 (3), 265-283.
7. Boldrin, M., Levine, D.K. (2002), The case against intellectual property. American Economic Review: Papers and Proceedings 92 (2), 209-212.
8. Brown, G. (2004), Speech by the RT Gordon Brown MP, Chancellor of the Exchequer at the BBC World Service Trust Conference, 24 November. Available at: http://www.hm-treasury.gov.uk/newsroom-and-speeches/press/2004/press-94-04.cfm. (Last accessed on December 1, 2007.)
9. Chien, C. (2003), Cheap drugs at what price to innovation: Does the compulsory licensing of pharmaceuticals hurt innovation. Berkeley Technology Law Journal 18 (3), 853-908.
10. Civan, A., Maloney, M.T. (2006), The determinants of pharmaceutical research and development investments. Contributions to Economic Analysis & Policy 5 (1), 1-36. Article 28.
11. Cohen, J.C., Lybecker, K.M. (2005), AIDS policy and pharmaceutical patents: Brazil's strategy to safeguard public health. World Economy 28 (2), 211-230.
12. Correa, C.M. (1999), Intellectual Property Rights and the Use of Compulsory Licenses: Options for Developing Countries. The South Centre, Geneva, Switzerland.
13. Danzon, P.M. (1997), Price discrimination for pharmaceuticals: Welfare effects in the United States and the European Union. International Journal of the Economics of Business 4 (3), 301-321.
14. Danzon, P.M., Towse, A. (2003), Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. International Journal of Health Care Finance and Economics 3 (3), 183-205.
15. DiMasi, J.A., Hansen, W., Grabowski, H.G. (2003), The price of innovation: New estimates of drug development costs. Journal of Health Economics 22 (2), 151-185.
16. Finkelstein, A. (2004), Static and dynamic effects of health policy: Evidence from the vaccine industry. Quarterly Journal of Economics 119 (2), 527-564.
17. Ganslandt, M., Maskus, K.E. (2004), The price impact of parallel imports in pharmaceuticals: Evidence from the European Union. Journal of Health Economics 23 (5), 1035-1057.
18. Ganslandt, M., Maskus, K.E., Vivian Wong, E. (2001), Developing and distributing essential drugs to poor countries: The DEFEND proposal. World Economy 24 (6), 779-795.
19. Giacotto, C., Santerre, R.E., Vernon, J.A. (2005), Drug prices and research and development investment behavior in the pharmaceutical industry. Journal of Law & Economics 48 (1), 195-214.
20. Gilbert, R., Shapiro, C. (1990), Optimal patent length and breadth. RAND Journal of Economics 21 (1), 106-112.
21. Ginarte, J.C., Park,W.G. (1997), Determinants of patent rights: A cross-national study. Research Policy 26 (3), 283-301.
22. Grossman, G.M., Lai, E.L.-C. (2004), International protection of intellectual property. American Economic Review 94 (5), 1635-1653.
23. Gwartney, J., Lawson, R. (1997), Economic Freedom of the World: 1997 Report. Fraser Institute, Vancouver.
24. Hausman, J.A., MacKie-Mason, J.K. (1988), Price discrimination and patent policy. RAND Journal of Economics 19 (2), 253-265.
25. Hornbeck, R.A. (2005), Price discrimination and smuggling of AIDS drugs. Journals in Economic Analysis and Policy: Topics in Economic Analysis and Policy 5 (1), 1-25.
26. Kanavos, P., Costa-Font, J. (2005), Pharmaceutical parallel trade in Europe: Stakeholder and competition effects. Economic Policy 20 (44), 751-798.
27. Kawaura, A., La Croix, S.J. (1995), Japan's shift from process to product patents in the pharmaceutical industry. Economic Inquiry 33 (1), 88-103.
28. Konan, D.E., La Croix, S.J., Roumasset, J., Heinrich, J. (1995), Intellectual property rights in the Asia-Pacific region: Problems, patterns, and policy. Asian-Pacific Economic Literature 9 (2), 13-35.
29. Kremer, M. (1998), Patent buyouts: A mechanism for encouraging innovation. Quarterly Journal of Economics 113 (4), 1137-1167.
30. Kremer, M. (2002), Pharmaceuticals and the developing world. Journal of Economic Perspectives 16 (4), 67-90.
31. Kremer, M., Glennerster, R. (2004), Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton University Press, Princeton, NJ.
32. Kyle, M. (2006), The role of firm characteristics in pharmaceutical product launches. RAND Journal of Economics 37 (3), 602-618.
33. Kyle, M. (2007), Pharmaceutical price controls and entry strategies. Review of Economics and Statistics 89 (1), 88-99.
34. La Croix, S.J., Konan, D.E. (2007), Is intellectual property protection unfair to developing countries? In: Petri, P.A., La Croix, S.J. (Eds.), Challenges to the Global Trading System: Adjustment to Globalization in the Asia-Pacific Region. Routledge, New York/London.
35. Lanjouw, J.O. (1998), The introduction of pharmaceutical product patents in India: "Heartless exploitation of the poor and suffering?". National Bureau of Economic Research Working Paper No. 6366. Cambridge, MA.
36. Lanjouw, J.O. (2002a), Intellectual property and the availability of pharmaceuticals in poor countries. Innovation Policy and the Economy 3, 91-130.
37. Lanjouw, J.O. (2002b), A patent policy for global diseases: U.S. international legal issues. Harvard Journal of Law & Technology 16 (1), 85-124.
38. Lanjouw, J.O. (2005), Patents, price controls and access to new drugs: How policy affects global market entry. National Bureau of Economic Research Working Paper, No. 11321. Cambridge, MA.
39. Lanjouw, J.O., Cockburn, I.M. (2001), New pills for poor people? Empirical Evidence after GATT. World Development 29 (2), 265-289.
40. Lichtenberg, F.R. (2001), The effect of new drugs on mortality from rare diseases and HIV. National Bureau of Economic ResearchWorking Paper, No. 8677. Cambridge, MA.
41. Lichtenberg, F.R. (2004), The effect of drug vintage on survival: Micro evidence from Puerto Rico's medicaid program. National Bureau of Economic Research Working Paper, No. 10884. Cambridge, MA.
42. Lichtenberg, F.R. (2005a), The impact of new drug launches on longevity: Evidence from longitudinal, disease-level data from 52 countries, 1982-2001. International Journal of Health Care Finance and Economics 5 (1), 47-73.
43. Lichtenberg, F.R. (2005b), Pharmaceutical innovation and the burden of disease in developing and developed countries. Journal of Medicine and Philosophy 30 (6), 663-690.
44. Lichtenberg, F.R., Philipson, T.J. (2002), The dual effects of intellectual property regulations: within-and between-patent competition in the U.S. pharmaceutical industry. Journal of Law & Economics 45 (2), 643-672. Pt. 2.
45. Liu, M., La Croix, S.J. (2007), A cross-country index of intellectual property rights for pharmaceutical innovations. Unpublished Manuscript. Department of Economics, University of Hawaii-Manoa.
46. Lovell, C.A.K.,Wertz, K.L. (1981), Price discrimination in related markets. Economic Inquiry 19 (3), 488-494.
47. Lu, Z.J., Comanor, W.S. (1998), Strategic pricing of pharmaceuticals. Review of Economics and Statistics 80 (1), 108-118.
48. Madera, T. (2003), The backlash against orphan drugs. Scientific American 288 (5), 81-87.
49. Malueg, D.A., Schwartz, M. (1994), Parallel imports, demand dispersion, and international price discrimination. Journal of International Economics 37, 187-196.
50. Maskus, K.E. (2000a), Parallel imports. World Economy 23 (9), 1269-1284.
51. Maskus, K.E. (2000b), Intellectual Property Rights in the Global Economy. The Institute for International Economics, Washington, DC.
52. Maskus, K.E. (2001), Parallel Imports in Pharmaceuticals: Implications for Prices and Competition in Developing Countries. Final Report to the World Intellectual Property Organization, Geneva. Available at: http://www.wipo.int/ about-ip/en/studies/pdf/ssa-maskus-pi.pdf. (Last accessed on April 25, 2007.)
53. Maskus, K.E. (2002), Ensuring access to essential medicines: Some economic considerations. Wisconsin International Law Journal 20 (3), 563-580.
54. Maskus, K.E., Konan, D.E. (1994), Trade-related intellectual property rights: Issues and exploratory results. In: Deardorff, A.V., Stern, R.M. (Eds.), Analytical and Negotiating Issues in the World Trading System. University of Michigan Press, Ann Arbor.
55. Maskus, K.E., Lahouel, M. (2000), Competition policy and intellectual property rights in developing countries. World Economy 23 (4), 595-611.
56. McFetridge, D.G. (1997), Intellectual Property Rights and the Location of Innovative Activity: The Canadian Experience with Compulsory Licensing of Patented Pharmaceuticals. Paper Prepared for Presentation at the NBER Summer Institute, July 29, 1997. Available at: http://http-server.carleton.ca/~dmcfet/ personal/NBER.PDF. (Last accessed on March 20, 2007.)
57. Ministry of Public Health and National Health Security Office, Government of Thailand (2007), Facts and Evidences on the Ten Burning Issues Related to the Government Use of Patents on Three Essential Drugs in Thailand. Sangsue Co., Ltd., Bangkok.
58. Mitchell, M.F., Llobet, G., Hopenhayn, H. (2006), Rewarding sequential inventors: Patents, prizes, and buyouts. Journal of Political Economy 115 (6), 1041-1068.
59. Morel, C.M., Acharya, T., Broun, D., Dangi, A., Elias, C., Ganguly, N.K., Gardner, C.A., Gupta, R.K., Haycock, J., Heher, A.D., Hotez, P.J., Kettler, H.E., Keusch, G.T., Krattiger, A.F., Kreutz, F.T., Lall, S., Lee, K., Mahoney, R., Martinez-Palomo, A., Mashelkar, R.A., Matlin, S.A., Mzimba, M., Oehler, J., Ridley, R.G., Senanayake, P., Singer, P., Yun, M. (2005), Health innovation networks to help developing countries address neglected diseases. Science 309 (5733), 401-404.
60. Morton, F.M.S. (1999), Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30 (3), 421-440.
61. Nogues, J. (1990), Patents and pharmaceutical drugs: Understanding the pressures on developing countries. Journal of World Trade Law 24 (6), 81-104.
62. Nordhaus, W.D. (1969), Invention, Growth and Welfare: A Theoretical Treatment of Technological Change. MIT Press, Cambridge, MA.
63. Posen, H.E. (2005), Three essays on innovation and the impact of capital markets. Unpublished Dissertation. University of Pennsylvania.
64. Qian, Y. (2007), Do national patent laws stimulate domestic innovation in a global patenting environment? A cross-country analysis of pharmaceutical patent protection, 1978-2002. Review of Economics and Statistics 89 (3), 436-453.
65. Ramsey, F.P. (1927), A contribution to the theory of taxation. Economic Journal 37 (145), 47-61.
66. Reichman, J.H., Hasenzahl, C. (2002), Non-voluntary Licensing of Patented Inventions: History, TRIPS, and Canadian and United States Practice. Bridges Weekly, 7 October: 3, 4, and 10. Available at: http://www.iprsonline.org/ictsd/ docs/ReichmanBridgesYear6N7Oct2002.pdf. (Last accessed on March 27, 2007.)
67. Scherer, F.M. (1977), The Economic Effects of Compulsory Patent Licensing. New York University Monograph Series in Finance and Economics. Graduate School of Business Administration, Center for the Study of Financial Institutions.
68. Scherer, F.M. (2004a), A note on global welfare in pharmaceutical patenting. World Economy 27 (7), 1127-1142.
69. Scherer, F.M. (2004b), The pharmaceutical industry: Prices and progress. New England Journal of Medicine 351 (9), 927-932.
70. Scherer, F.M., Watal, J. (2002), Post-trips options for access to patented medicines in developing nations. Journal of International Economic Law 5 (4), 913-939.
71. Schmalensee, R. (1981), Output and welfare implications of monopolistic third-degree price discrimination. American Economic Review 71 (1), 242-247.
72. Scotchmer, S. (2005), Innovation and Incentives. MIT Press, Cambridge, MA.
73. Tandon, P. (1982), Optimal patents with compulsory licensing. Journal of Political Economy 90 (3), 470-486.
74. Tirole, J. (1988), The Theory of Industrial Organization. MIT Press, Cambridge, MA.
75. United Kingdom Parliament, Parliamentary Office of Science and Technology (2005). Fighting Diseases of Developing Countries. Postnote 241. June. Available on-line at: http://www.parliament.uk/documents/upload/postpn241.pdf. (Last accessed on March 26, 2007.)
76. United Nations Program on AIDS (2006), 2006 Report on the Global AIDS Epidemic. UNAIDS, Geneva.
77. United States Office of Technology Assessment (1993), Pharmaceutical R&D: Costs, Risks, and Rewards. U.S. Government Printing Office, Washington, DC.
78. Van de Perre, P., Dedet, J. (2004), Vaccine efficacy:Winning a battle (not war) against malaria. Lancet 364 (9443), 1380-1383.
79. Varian, H.R. (1985), Price discrimination and social welfare. American Economic Review 75 (4), 870-875.
80. Varian, H.R. (1989), Price discrimination. In: Schmalensee, R., Willig, R. (Eds.), Handbook of Industrial Organization. North-Holland, New York.
81. Vernon, J.A. (2005), Examining the link between price regulation and pharmaceutical R&D investment. Health Economics 14 (1), 1-16.
82. World Health Organization (2001a), WHO Medicines Strategy, Revised Procedure for Updating WHO's Model List of Essential Drugs, Report by the WHO Secretariat. WHO, Geneva, Switzerland. Available on-line at: http://www.who.int/gb/ebwha/pdf-files/EB109/eeb1098.pdf. (Last accessed on April 28, 2007.)
83. World Health Organization (2001b), Globalization, TRIPS and Access to Pharmaceuticals. WHO Policy Perspectives on Medicines, No. 3. WHO, Geneva, Switzerland.
84. World Health Organization (2004), Equitable Access to Essential Medicines: A Framework for Collective Action. WHO, Geneva, Switzerland. Available on-line at: http://whqlibdoc.who.int/hq/2004/WHO-EDM-2004.4.pdf. (Last accessed on April 28, 2007.)
85. World Health Organization (2005), The WHO Model List of Essential Medicines, 14th ed.WHO, Geneva, Switzerland. Available online at: http://whqlibdoc.who.int/hq/2005/a87017-eng.pdf. (Last accessed on April 28, 2007.)
86. World Health Organization, Commission on Macroeconomics and Health (2002), Health and the International Economy: The Report of Working Group 4 of the Commission on Macroeconomics and Health. WHO, Geneva, Switzerland.
87. Yin, W. (2006), Do market incentives generate innovation or balkanization? Evidence from the market for rare disease drugs. Unpublished Manuscript. Harris School of Public Policy, University of Chicago.